- Home
- ANVS vs PBYI Comparison
ANVS vs PBYI Comparison
Compare ANVS & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- PBYI
- Stock Information
- Founded
- ANVS 2008
- PBYI 2010
- Country
- ANVS United States
- PBYI United States
- Employees
- ANVS N/A
- PBYI N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- ANVS Health Care
- PBYI Health Care
- Exchange
- ANVS Nasdaq
- PBYI Nasdaq
- Market Cap
- ANVS 110.4M
- PBYI 126.5M
- IPO Year
- ANVS 2020
- PBYI N/A
- Fundamental
- Price
- ANVS $6.85
- PBYI $2.42
- Analyst Decision
- ANVS Strong Buy
- PBYI Strong Buy
- Analyst Count
- ANVS 6
- PBYI 1
- Target Price
- ANVS $29.67
- PBYI $7.00
- AVG Volume (30 Days)
- ANVS 261.0K
- PBYI 524.8K
- Earning Date
- ANVS 11-08-2024
- PBYI 11-07-2024
- Dividend Yield
- ANVS N/A
- PBYI N/A
- EPS Growth
- ANVS N/A
- PBYI 492.79
- EPS
- ANVS N/A
- PBYI 0.47
- Revenue
- ANVS N/A
- PBYI $243,569,000.00
- Revenue This Year
- ANVS N/A
- PBYI N/A
- Revenue Next Year
- ANVS N/A
- PBYI N/A
- P/E Ratio
- ANVS N/A
- PBYI $5.20
- Revenue Growth
- ANVS N/A
- PBYI 6.30
- 52 Week Low
- ANVS $4.53
- PBYI $2.23
- 52 Week High
- ANVS $22.49
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- ANVS 30.84
- PBYI 36.08
- Support Level
- ANVS $7.30
- PBYI $2.83
- Resistance Level
- ANVS $8.93
- PBYI $3.25
- Average True Range (ATR)
- ANVS 0.56
- PBYI 0.29
- MACD
- ANVS -0.26
- PBYI -0.04
- Stochastic Oscillator
- ANVS 4.89
- PBYI 6.03
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.